Dennis Langer - Oct 14, 2025 Form 4 Insider Report for Quoin Pharmaceuticals, Ltd. (QNRX)

Role
Director
Signature
/s/ Dennis Langer
Stock symbol
QNRX
Transactions as of
Oct 14, 2025
Transactions value $
$128,640
Form type
4
Date filed
10/15/2025, 05:15 PM
Previous filing
Aug 25, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
LANGER DENNIS Director C/O QUOIN PHARMACEUTICALS LTD.,, 42127 PLEASANT FOREST COURT, ASHBURN /s/ Dennis Langer 2025-10-15 0001274225

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction QNRX ADSs Purchase $129K +15.2K +1515200% $8.49 15.2K Oct 14, 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction QNRX Series H Warrants (Right to Buy) Purchase +15.2K 15.2K Oct 14, 2025 ADS 15.2K $9.08 Direct F1, F2, F3, F4
transaction QNRX Series I Warrants (Right to Buy) Purchase +15.2K 15.2K Oct 14, 2025 ADS 15.2K $10.31 Direct F1, F2, F3, F5
transaction QNRX Series J Warrants (Right to Buy) Purchase +15.2K 15.2K Oct 14, 2025 ADS 15.2K $12.38 Direct F1, F2, F3, F6
transaction QNRX Series K Warrants (Right to Buy) Purchase +15.2K 15.2K Oct 14, 2025 ADS 15.2K $12.38 Direct F1, F2, F3, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.
F2 Each ADS purchased together with a Series H Warrant, a Series I Warrant, a Series J Warrant and a Series K Warrant to purchase one ADS in the Issuer's private placement which closed on October 14, 2025, at a combined price of $8.49. The Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants are collectively referred to as the "Warrants."
F3 The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.
F4 The Series H Warrants will expire on the earlier of (i) five (5) years from the Closing Date or (ii) 30 days after the Company's public announcement that the Company has received Type C meeting minutes from the FDA indicating openness to baseline-controlled pivotal studies for QRX003 for the treatment of Netherton Syndrome.
F5 The Series I Warrants will expire as follows: (i) 50% of the Series I Warrants will expire on the earlier of (A) five (5) years from the Closing Date or (B) 30 days after the Company's public announcement that the primary endpoint has been met in the monotherapy pivotal trial of QRX003 for the treatment of Netherton Syndrome, and (ii) 50% of the Series I Warrants will expire on the earlier of (A) five (5) years from the Closing Date or (B) 30 days after the Company's public announcement that the primary endpoint has been met in the adjuvant pivotal trial of QRX003 for the treatment of Netherton Syndrome.
F6 The Series J Warrants will expire on the earlier of (i) five (5) years from the Closing Date or (ii) 30 days after the public announcement of the receipt of either accelerated or traditional approval by the FDA of QRX003 for the treatment of Netherton Syndrome.
F7 The Series K Warrants will expire on the earlier of (i) five (5) years from the Closing Date or (ii) 30 days after the public announcement of the Company's sale of a Priority Review Voucher (PRV).